Skip to main content
Research ArticleOpen accessIn the author namesBridging Innovation and Access: Randomized, Single-Dose, Open-Label, Parallel-Group Bioequivalence Study of Generic and Innovator Injection Semaglutide in IndiaMayur Madhav Mayabhate, Nitin Kapure, Akhilesh Sharma, Radhakrishna VaddemSemaglutide, a long-acting Glucagon-Like Peptide-1 (GLP-1) receptor agonist, is effective in improving glycemic control, reducing body weight, and lowering cardiovascular risk in Type 2 Diabetes Mellitus (T2DM). Limited accessibility of the innovator formulation underscores the need for bioequivalent generic alternatives. To assess the pharmacokinetic bioequivalence of a synthetic Semaglutide Injection (2 mg/1.5 mL) developed by Alkem Laboratories Ltd., India, compared … …American Journal of Pharmacology and Toxicology, Vol. 20, Issue 1 · 20 Apr 2026 · 2,626 accessesView PDFCite